Tislelizumab Shows Promise in Pre Surgical Rectal Cancer
New findings indicate that the drug Tislelizumab significantly boosts tumour response in patients undergoing pre surgical treatment for rectal cancer. This development, highlighted by EMJ, offers a promising advancement in oncology.
Read More